No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 529.6x · 10Y median 127.0x · 89th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:04:23.944Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Shattuck Labs, Inc. (STTK) stock was $5.86 as of Oct 6, 2026, 4:00 PM EDT, down 9.85% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +175.3% · 3-year avg +66.8%/yr · 5-year avg -20.1%/yr
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage.
Biotechnology · Austin, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-0.10
Revenue Est.
$37500.00
Last Quarter Results
EPS
$-0.12
vs Estimate
$-0.12
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1STTK | $529.58M | $5.86 | -9.85% | +175.26% | -20.11% | N/A | N/A |
| 2NVCT | $531.52M | $20.03 | -6.36% | +253.76% | N/A | N/A | vs STTK |
| 3DCTH | $531.98M | $15.41 | -2.90% | +42.73% | +10.90% | N/A | vs STTK |
| 4MNPR | $533.04M | $79.57 | +1.63% | -21.14% | +27.38% | N/A | vs STTK |
| 5IMMX | $524.43M | $9.64 | -4.84% | +388.03% | N/A | N/A | vs STTK |
| 6PROK | $538.01M | $1.60 | +1.27% | -42.18% | -30.65% | N/A | vs STTK |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$15.22
+159.8% upside
Low
$10.00
Current
$5.86
High
$19.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.14 | $-0.11 | $-0.09 | 8 |
| Quarter ending Dec 2026 | $-0.14 | $-0.12 | $-0.10 | 8 |
| Quarter ending Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 3 |
| Quarter ending Jun 2027 | $-0.12 | $-0.12 | $-0.12 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.56 | $-0.49 | $-0.44 | 8 |
| FY 2027 | $-0.66 | $-0.53 | $-0.38 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $37500.00 | $37500.00 | $37500.00 | 4 |
| Quarter ending Dec 2026 | $100000.00 | $100000.00 | $100000.00 | 5 |
| Quarter ending Mar 2027 | $60000.00 | $60000.00 | $60000.00 | 4 |
| Quarter ending Jun 2027 | $60000.00 | $60000.00 | $60000.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $105000.00 | $105000.00 | $105000.00 | 6 |
| FY 2027 | $110250.00 | $110250.00 | $110250.00 | 6 |
